Regentis Biomaterials LtdRGNT
Price$1.83

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$13.6M-384.3% YoYTTM through 31 Dec 2025
Free Cash Flow -$1.4MTTM through 31 Dec 2025

Margins

Current
Gross Margin0.0%

Returns

-288.9%ROE
-179.7%ROA

Balance Sheet Health

Debt / Equity0.25x
Current Ratio2.66x
Net Debt-$6.2Mnet cash position
Cash & Equivalents$7.4M

Quality Metrics

Piotroski F-Score1 / 9

Multi-Year Trend

Diluted EPS
'23'24'25
FY2025: $-24.08

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Regenerative Medicine$00.0%
View details

Preparations are underway for European commercial launch with surgeon training scheduled to commence in Q3 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.